When Medtronic PLC (NYSE: MDT) reported its most recent quarterly results before the markets opened on Tuesday, the medical device company said that it had $0.62 in earnings per share (EPS) and $6.5 billion in revenue. Consensus estimates that called for $0.18 in EPS and $5.44 billion in revenue, and the fiscal first quarter of last year reportedly had $1.26 in EPS and $7.49 billion in revenue.
During the first quarter, U.S. revenue represented 52% of the total company revenue, coming in at $3.35 billion. U.S. revenue decreased 14% year over year. Non-U.S. developed market revenue was reported as $2.175 billion, which represented 33% of company revenue and decreased 8% from last year. Emerging Markets revenue was $981 million and represented 15% of company revenue.
The Cardiac and Vascular Group (CVG) revenues decreased 13% year over year to $2.43 billion. The group’s revenue reflected a year-over-year decline in procedure volumes as a result of the COVID-19 pandemic, but the revenue did improve sequentially.
Breaking down the CVG further, Cardiac Rhythm & Heart Failure revenue decreased 10% to $1.247 billion. Coronary & Structural Heart revenues fell 17% to $780 million. Aortic, Peripheral & Venous revenues dropped 13% to $405 million.
The Minimally Invasive Therapies Group revenues decreased 14% to $1.80 billion. This consisted of Surgical Innovations with revenues of $1.08 billion and Respiratory, Gastrointestinal & Renal revenues of $720 million.
Restorative Therapies group decreased 15% to $1.71 billion, which saw decreases in Cranial and Spinal Technologies, Specialty Therapies, and Neuromodulation.
Diabetes Group revenue fell 5% year over year to $562 million. This group’s revenue performance was affected by a delay in new patient starts on insulin pumps and continued competitive pressure.
The company did not issue any guidance regarding the coming quarter, citing uncertainty regarding COVID-19. Analysts are calling for $0.79 in EPS and $6.8 billion in revenue for the fiscal second quarter.
Medtronic stock traded up about 4% on Tuesday to $103.90, in a 52-week range of $72.13 to $122.15. The consensus price target is $109.50.
Get Ready To Retire (Sponsored)
Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Get started right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
